Johnnetta Betsch Cole is an American anthropologist, museum director, college president. Cole was the first female African-American president of Spelman College, a black college, serving from 1987 to 1997, she was president of Bennett College from 2002 to 2007. During 2009–2017 she was Director of the Smithsonian Institution's National Museum of African Art. Johnnetta Betsch was born in Jacksonville, Florida, on October 19, 1936, her family belonged to the African-American upper class. Sammis' great-grandparents were Zephaniah Kingsley, a slave trader and slave owner, his wife and former slave Anna Madgigine Jai, a Wolof princess, from present-day Senegal, her Fort George Island home is protected as a National Historic Landmark. Cole enrolled at the age of 15 in Fisk University, a black college, she transferred to Oberlin College in Ohio, where she completed a Bachelor of Arts degree in sociology in 1957. She attended graduate school at Northwestern University, earning her Master of Arts and Doctor of Philosophy degrees in anthropology.
She did her dissertation field research in Liberia, West Africa, in 1960–1961 through Northwestern University as part of their economic survey of the country. Cole served as a professor at Washington State University from 1962 to 1970, where she cofounded one of the US's first black studies programs. In 1970 Cole began working in the Department of Anthropology at the University of Massachusetts Amherst, where she served until 1982. While at the University of Massachusetts, she played a pivotal role in the development of the university's W. E. B. Du Bois Department of African-American Studies. Cole moved to Hunter College in 1982, became director of the Latin American and Caribbean Studies program. From 1998 to 2001 Cole was a professor of Anthropology, Women's Studies, African American Studies at Emory University in Atlanta. In 1987, Cole was selected as the first black female president of Spelman College, a prestigious black college for women, she served until 1997, building up their endowment through a $113 million capital campaign, attracting higher enrollment as students increased, overall, the ranking of the school among the best liberal arts schools went up.
Bill and Camille Cosby contributed $20 million to the capital campaign. After teaching at Emory University, she was recruited as president of Bennett College for Women a black college for women. There she led another successful capital campaign. In addition, she founded an art gallery to contribute to the college's culture. Cole is the Chair of the Johnnetta B. Cole Global Diversity & Inclusion Institute founded at Bennett College for Women, she is a member of Delta Sigma Theta sorority. She was Director of the National Museum of African Art, part of the Smithsonian Institution in Washington, DC, during 2009–2017. During her directorship the controversial exhibit, "Conversations: African and African-American Artworks in Dialogue," featuring dozens of pieces from Bill and Camille Cosby's private art collection was held in 2015, coinciding with accusations of sexual assault against the comedian. Cole has served in major corporations and foundations. Cole served for many years as board member at the prestigious Rockefeller Foundation.
She has been a director of Merck & Co. since 1994. She is the first woman elected to the board of Coca-Cola. From 2004 to 2006, Cole was the Chair of the Board of Trustees of United Way of America and is on the Board of Directors of the United Way of Greater Greensboro. Since 2013, Cole has been listed on the Advisory Council of the National Center for Science Education. President-elect Bill Clinton appointed Cole to his transition team for education, the arts, humanities in 1992, he considered her for the cabinet post of Secretary of Education. But when The Jewish Daily Forward reported that she had been a member of the national committee of the Venceremos Brigades, which the Federal Bureau of Investigation had tied to Cuban intelligence forces, Clinton did not advance her nomination. In 2018 she was awarded the Legend in Leadership Award for Higher Education from the Yale Chief Executive Leadership Institute American Alliance of Museums Honors Dr. Johnnetta Cole with 2017 Award for Distinguished Service to Museums In 2013, Cole received the highest citation of the International Civil Rights Center & Museum, the Alston-Jones International Civil and Human Rights Award.
Cole has received more than 40 honorary degrees, including those from Williams College and Bates College in 1989, Oberlin College in 1995, Mount Holyoke College in 1998, Mills College in 1999, Howard University and North Carolina A&T State University in 2009. She received honorary membership in Phi Beta Kappa from Yale in 1996, has served as a Phi Beta Kappa Senator, she received a Candace Award from the National Coalition of 100 Black Women in 1988. I pose that question to myself, why, in the 107 years of the history of this Black college for women, there has not been an African-American woman president; this is a nation whose written vision is chillingly beautiful. The more we pull together toward a new day, the less it matters what pushed us apart in the past We are for difference: for respecting difference for allowing difference, for encouraging difference, until difference no longer makes a difference; the ultimate expression of generosity is not in giving of what you have, but in giving of who you are.
2002 Voices from the Gaps At 80, Johnnetta Cole reflects on her career and t
The Merck Index is an encyclopedia of chemicals and biologicals with over 10,000 monographs on single substances or groups of related compounds published online by the Royal Society of Chemistry. The first edition of the Merck's Index was published in 1889 by the German chemical company Emanuel Merck and was used as a sales catalog for Merck's growing list of chemicals it sold; the American subsidiary was established two years and continued to publish it. During World War I the US government seized Merck's US operations and made it a separate American "Merck" company that continued to publish the Merck Index. In 2012 the Merck Index was licensed to the Royal Society of Chemistry. An online version of The Merck Index, including historic records and new updates not in the print edition, is available through research libraries, it includes an appendix with monographs on organic named reactions. The current edition is the 15th, published in April 2013. Monographs in The Merck Index contain: a CAS registry number synonyms of the substance, such as trivial names and International Union of Pure and Applied Chemistry nomenclature a chemical formula molecular weight percent composition a structural formula a description of the substance's appearance melting point and boiling point solubility in solvents used in the laboratory citations to other literature regarding the compound's chemical synthesis a therapeutic category, if applicable caution and hazard information 1st - first edition released by E.
Merck 2nd - second edition released by Merck's American subsidiary and added medicines from the United States Pharmacopeia and National Formulary 3rd 4th 5th 6th 7th - first named editor is Merck chemist Paul G. Stecher. 8th - editor Paul G. Stecher 9th - editor Martha Windholz, a Merck chemist. 10th, ISBN 0-911910-27-1 - editor Martha Windholz. In 1984 the Index became available online as well as printed. 11th, ISBN 0-911910-28-X 12th, ISBN 0-911910-12-3 - editor Susan Budavari, a Merck chemist. 13th, ISBN 0-911910-13-1 - editor Maryadele O'Neil, senior editor at Merck. 14th, ISBN 978-0-911910-00-1 - editor Maryadele O'Neil 15th, ISBN 978-1-84973670-1 - editor Maryadele O'Neil, first edition under the Royal Society of Chemistry. List of academic databases and search engines The Merck Manual of Diagnosis and Therapy The Merck Veterinary Manual Home Health and Pet Health Official website
Royal Society of Chemistry
The Royal Society of Chemistry is a learned society in the United Kingdom with the goal of "advancing the chemical sciences". It was formed in 1980 from the amalgamation of the Chemical Society, the Royal Institute of Chemistry, the Faraday Society, the Society for Analytical Chemistry with a new Royal Charter and the dual role of learned society and professional body. At its inception, the Society had a combined membership of 34,000 in the UK and a further 8,000 abroad; the headquarters of the Society are at Burlington House, London. It has offices in Thomas Graham House in Cambridge where RSC Publishing is based; the Society has offices in the United States at the University City Science Center, Philadelphia, in both Beijing and Shanghai and Bangalore, India. The organisation carries out research, publishes journals and databases, as well as hosting conferences and workshops, it is the professional body for chemistry in the UK, with the ability to award the status of Chartered Chemist and, through the Science Council the awards of Chartered Scientist, Registered Scientist and Registered Science Technician to suitably qualified candidates.
The designation FRSC is given to a group of elected Fellows of the society who have made major contributions to chemistry and other interface disciplines such as biological chemistry. The names of Fellows are published each year in The Times. Honorary Fellowship of the Society is awarded for distinguished service in the field of chemistry; the president is elected biennially and wears a badge in the form of a spoked wheel, with the standing figure of Joseph Priestley depicted in enamel in red and blue, on a hexagonal medallion in the centre. The rim of the wheel is gold, the twelve spokes are of non-tarnishable metals; the current president is Dame Carol V. Robinson. Past presidents of the society have been: The following are membership grades with post-nominals: Affiliate: The grade for students and those involved in chemistry who do not meet the requirements for the following grades. AMRSC: Associate Member, Royal Society of Chemistry The entry level for RSC membership, AMRSC is awarded to graduates in the chemical sciences.
MRSC: Member, Royal Society of Chemistry Awarded to graduates with at least 3 years' experience, who have acquired key skills through professional activity FRSC: Fellow of the Royal Society of Chemistry Fellowship may be awarded to nominees who have made an outstanding contribution to chemistry. HonFRSC: Honorary Fellow of the Society Honorary Fellowship is awarded for distinguished service in the field of chemistry. CChem: Chartered Chemist The award of CChem is considered separately from admission to a category of RSC membership. Candidates need to be MRSC or FRSC and demonstrate development of specific professional attributes and be in a job which requires their chemical knowledge and skills. CSci: Chartered Scientist The RSC is a licensed by the Science Council for the registration of Chartered Scientists. EurChem: European Chemist The RSC is a member of the European Communities Chemistry Council, can award this designation to Chartered Chemists. MChemA: Mastership in Chemical Analysis The RSC awards this postgraduate qualification, the UK statutory qualification for practice as a Public Analyst.
It requires candidates to submit a portfolio of suitable experience and to take theory papers and a one-day laboratory practical examination. The qualification GRSC was awarded from 1981 to 1995 for completion of college courses equivalent to an honours chemistry degree and overseen by the RSC, it replaced the GRIC offered by the Royal Institute of Chemistry. The society is organised around 9 divisions, based on subject areas, local sections, both in the United Kingdom and overseas. Divisions cover broad areas of chemistry but contain many special interest groups for more specific areas. Analytical Division for analytical chemistry and promoting the original aims of the Society for Analytical Chemistry. 12 Subject Groups. Dalton Division, named after John Dalton, for inorganic chemistry. 6 Subject Groups. Education Division for chemical education. 4 Subject Groups. Faraday Division, named after Michael Faraday, for physical chemistry and promoting the original aims of the Faraday Society. 14 Subject Groups.
Organic Division for organic chemistry. 6 Subject Groups. Chemical Biology Interface Division. 2 Subject Groups. Environment and Energy Division. 3 Subject Groups. Materials Chemistry Division. 4 Subject Groups. Industry and Technology Division. 13 Subject Groups. There are 12 subjects groups not attached to a division. There are 35 local sections covering the United Ireland. In countries of the Commonwealth of Nations and many other countries there are Local Representatives of the society and some activities; the society is a not-for-profit publisher: surplus made by its publishing business is invested to support its aim of advancing the chemical sciences. In addition to scientific journals, including its flagship journals Chemical Communications, Chemical Science and Chemical Society Reviews, the society publishes: Education in Chemistry for teachers. A free online journal for chemistry educators, Chemistry Education Research and Practice. A general chemistry magazine Chemistry World, sent monthly to all members of the Society throughout the world.
The editorial board consists of 10 industrial chemists. It was first published in January 2004, it replaced C
Richard Clark (business executive)
Richard T. Clark is a former Chairman of the Merck & Co. pharmaceutical company, a position he held from 2007 to 2011. His previous leadership positions at Merck & Co. include CEO, President of the Merck & Co. manufacturing division. A first generation college student, he attended Washington & Jefferson College, where he majored in history and was a member of Lambda Chi Alpha, he earned an MBA at the American University and was a lieutenant in the US Army 1970–1972. He was employed by Merck & Co. from 1972. He has served on Jefferson College Board of Trustees, he serves on the Board of Directors of Project HOPE and was Chairman from 2010 to October, 2018. While CEO of Merck & Co. in 2008, Richard T. Clark earned a total compensation of $17,320,938, which included a base salary of $1,783,334, a cash bonus of $2,244,510, stocks granted of $6,811,125, options granted of $6,408,300, other compensation of $73,669
Merck Manual of Diagnosis and Therapy
The Merck Manual of Diagnosis and Therapy, referred to as The Merck Manual, is the world's best-selling medical textbook, the oldest continuously published English language medical textbook. First published in 1899, the current print edition of the book, the 20th Edition, was published in 2018. In 2014, Merck decided to move The Merck Manual to digital-only, online publication, available in both Professional and Consumer versions; the Merck Manual of Diagnosis and Therapy is one of several medical textbooks, collectively known as The Merck Manuals, which are published by Merck Publishing, a subsidiary of the pharmaceutical company Merck Co. Inc. in the United States and Canada, MSD in other countries in the world. Merck formerly published The Merck Index, An Encyclopedia of Chemicals and Biologicals; the first edition of The Merck Manual was published in 1899 by Merck & Co. Inc. for physicians and pharmacists and was titled Merck’s Manual of the Materia Medica. The 192 page book which sold for US $1.00, was divided into three sections, Part I was an alphabetical listing of all known compounds thought to be of therapeutic value with uses and doses.
Many of the terms used are now considered archaic, such as abasia, astasia and rubefacients - sternutatories, many of the agents listed are now not considered to be standard therapeutic agents but were considered useful at the time, including poisonous compounds such as mercury, lead and arsenic. There were 108 remedies listed for indigestion, including alcohol, cocaine, gold chloride, morphine, nux vomica, silver nitrate, “Turkish baths ”. Bismuth, magnesium salts were on the list, which are ingredients found in many modern gastrointestinal treatments available today. Arsenic was recommended for over 100 illnesses including anemia, hydrophobia and impotence; the formulas include “aletris cordial”, a “uterine tonic and restorative”, which contained “aletris farinosa or True Unicorn combined with aromatics”. The manufacturer, Rio Chemicals of St. Louis was clear to differentiate the inclusion of true unicorn rather than false unicorn in its preparation; the earliest versions did contain drugs that are still in use today for the same purposes, for example digitalis for heart failure.
The second edition of The Merck Manual was published in 1901, was expanded to 282 pages and included new sections on poisons and antidotes and conversion charts, a detailed explanation of the metric system. The 5th edition, published in 1923 was delayed due to paper shortages caused by World War I, the release of the 6th edition was delayed until 1934 due to the Stock Market Crash; the editor of that edition, Dr. M. R. Dinkelspiel had overseen the growth and reorganization of the Manual to discuss specific diseases and treatment options, external specialists reviewed each section; the 8th edition of the Manual was delayed by World War II until 1950. The 13th edition, released in 1977 was the first time the textbook was produced using magnetic tape and IBM punch cards, the previous version having been typed on a manual typewriter; the Centennial Edition published in 1999 included a separate facsimile version of the 1899 1st edition. It is reported that both Admiral Richard E. Byrd took the book with him on his expedition to the South Pole in 1929 and Albert Schweitzer had a copy of The Merck Manual with him at his hospital mission in Africa in 1913.
The recommended doses given in Part 1 of 1901 edition of The Manual were for adults when given by mouth. It included the following dose adjustment recommendations: 1899 1901 1905 1911 1923 1934 1940 1950 1956 1961 1966 1972 1977 1982 1984 1992 1999 2006 2011 2018 The Merck Manual is organized, like many internal medicine textbooks, into organ systems which discuss each major diseases of that system, covering diagnosis and treatment, it provides a comprehensive yet concise compendium of medical knowledge into about 3500 pages, by emphasizing practical information of use to a practicing physician. In addition to 24 sections covering medical topics, it includes a pharmacology section listing drugs by generic and brand name, a list of drug interactions and a pill identifier, a News and Commentary section, videos on procedures and examination techniques and case histories, clinical calculators, conversion tables and other resources; the text is characterized by the combination of conciseness and being up-to-date.
It is updated continuously by an independent editorial board and over 300 peer reviewers that contribute to the textbook, which goes through an average of 10 revisions by both internal and external reviewers before publication. The internal editorial staff consists of 4 physician reviews, one executive editor and 4 non-medical lay editors; the latest version has been translated
Rofecoxib is a COX-2 selective nonsteroidal anti-inflammatory drug. It was marketed by Merck & Co. to treat osteoarthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, acute pain conditions and dysmenorrhea. Rofecoxib was approved in the US by the US Food and Drug Administration in May 1999, was marketed under the brand names Vioxx and Ceeoxx. Rofecoxib was available by prescription as an oral suspension. Rofecoxib gained widespread acceptance among physicians treating patients with arthritis and other conditions causing chronic or acute pain. Worldwide, over 80 million people were prescribed rofecoxib at some time. In September 2004, Merck voluntarily withdrew rofecoxib from the market because of concerns about increased risk of heart attack and stroke associated with long-term, high-dosage use. Merck withdrew the drug after disclosures that it withheld information about rofecoxib's risks from doctors and patients for over five years resulting in between 88,000 and 140,000 cases of serious heart disease.
Rofecoxib was one of the most used drugs to be withdrawn from the market. In the year before withdrawal, Merck had sales revenue of US$2.5 billion from Vioxx. In 2005 the FDA issued a memo concluding that data from large long-term controlled clinical trials do not demonstrate that COX-2 selective agents have a greater risk of serious CV events than non-selective NSAIDs; the FDA reinforced this position in 2015, stating that the available data support a dose and duration dependent class effect of an increased risk of serious adverse cardiovascular events for COX-2 selective and non-selective NSAIDs. In November 2017, Massachusetts-based Tremeau Pharmaceuticals announced its plan to return rofecoxib to market as a treatment for hemophilic arthropathy. Tremeau announced that the FDA had granted an orphan designation for TRM-201 for the treatment of HA, that they had received FDA feedback on their development plan. HA is a degenerative joint disease caused by recurrent intra-articular bleeding, it is the largest cause of morbidity in patients with hemophilia and has no approved treatment options in the United States.
Traditional NSAIDs are avoided in this population due to their effects on platelet aggregation and risk of gastrointestinal ulcers, high potency opioids are the current standard of care in treating HA. Cyclooxygenase has two well-studied isoforms, called COX-1 and COX-2. COX-1 mediates the synthesis of prostaglandins responsible for protection of the stomach lining, while COX-2 mediates the synthesis of prostaglandins responsible for pain and inflammation. By creating "selective" NSAIDs that inhibit COX-2, but not COX-1, the same pain relief as traditional NSAIDs is offered, but with reduced risk of fatal or debilitating peptic ulcers. Rofecoxib is a selective COX-2 inhibitor, or "coxib". Though the class of coxibs includes several agents, there are varying degrees of COX-2 selectivity among them, with celecoxib being the least COX-2 selective, rofecoxib and etoricoxib, being COX-2 selective. At the time of its withdrawal, rofecoxib was the only coxib approved in the United States with clinical evidence of its superior gastrointestinal adverse effect profile over conventional NSAIDs.
This was based on the VIGOR study, which compared the efficacy and adverse effect profiles of rofecoxib and naproxen. The therapeutic recommended dosages were 12.5, 25, 50 mg with an approximate bioavailability of 93%. Rofecoxib crossed the placenta and blood–brain barrier, took 1–3 hours to reach peak plasma concentration with an effective half-life of 17 hours; the metabolic products are cis-dihydro and trans-dihydro derivatives of rofecoxib which are excreted through urine. Rofecoxib was approved by the FDA to treat to treat osteoarthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, acute pain conditions and dysmenorrhea; when it was marketed, it gained widespread acceptance among physicians treating patients with arthritis and other conditions causing chronic or acute pain. A 2003 placebo-controlled small short-term study in India of 80 women with premenstrual acne vulgaris acne, were given rofecoxib or placebo for 2 cycles of 10 days suggest that "rofecoxib is effective in the management of premenstrual acne.
On March 11, 2009, Scott S. Reuben, former chief of acute pain at Baystate Medical Center, Mass. Revealed that data for 21 studies he had authored for the efficacy of the drug had been fabricated in order to augment the analgesic effects of the drugs. There is no evidence. Reuben was a former paid spokesperson for the drug company Pfizer; the retracted studies were not submitted to either the FDA or the European Union's regulatory agencies prior to the drug's approval. Drug manufacturer Merck had no comment on the disclosure. In addition to the reduced incidence of gastric ulceration, rofecoxib exhibits no effect on bleeding time or platelet aggregation at supra-therapeutic doses. Aside from these features, rofecoxib exhibits a similar adverse effect profile to other NSAIDs; the VIGOR study, conducted by Bombardier, et al. compared the efficacy and adverse effect profiles of a supra-therapeutic dose of rofecoxib vs. a common dose of naproxen, had indicated a significant 4-fold increased risk of acute myocardial infarction in rofecoxib patients when compared wit
The Merck Group and known as Merck, is a German multinational pharmaceutical and life sciences company headquartered in Darmstadt, with around 50,000 employees in around 70 countries. Merck was founded in 1668 and is the world's oldest operating chemical and pharmaceutical company, as well as one of the largest pharmaceutical companies in the world. Merck operates in Europe, Asia and the Americas, it has major research and development centres in Darmstadt, Boston and Beijing. Merck pioneered the commercial manufacture of morphine in the 19th century and for a time held a virtual monopoly on cocaine. Merck was owned until going public on the Frankfurt Stock Exchange in 1995, is listed on the DAX index of Germany's top companies; the Merck family still controls a majority 70.3% of the company's shares. The Merck Group includes around 250 companies in 180 countries. Merck oHG, which now operates as a holding company; the American pharmaceutical company Merck & Co. was established as a subsidiary of Merck in 1891, but was nationalized by the United States in 1917, before being privatized again when George W. Merck purchased back the stock in 1919.
It is known as MSD outside of North America. The original Merck of Darmstadt holds the rights to the name Merck in all countries except the U. S. and Canada, where it is known as EMD. In 2015 Merck adopted a new uniform brand identity for all its subsidiaries, the company has stressed its intention to protect the brand of "the real Merck" globally and initiated litigation against its former subsidiary over use of the name. In 2018, the company celebrated their 350th anniversary; the roots of Merck reach back as far as the 17th century in Germany. In 1668, Friedrich Jacob Merck, an apothecary, assumed ownership of the Engel-Apotheke in Darmstadt, Germany. In 1816, Emanuel Merck, a descendant of the original founder, took over the pharmacy. Thanks to his scientific education he was successful in isolating and characterizing several different alkaloids in the pharmacy's laboratory, by doing so invented a number of drugs, he began the manufacture of these substances "in bulk" in 1827, touting them as a "Cabinet of Pharmaceutical and Chemical Innovations".
He and his successors built up a chemical-pharmaceutical factory that produced — in addition to raw materials for pharmaceutical preparations — a multitude of other chemicals and medicines. In 1891, Georg Merck set up Merck & Co. in New York. Merck & Co. was confiscated following the First World War and set up as an independent company in the United States. Today, the US company, which operates as Merck Sharp and Dohme outside the U. S. and Canada, has about 86,000 employees in 120 countries. It is one of the top 5 pharmaceutical companies worldwide, larger than its German ancestor, which employs around 40,700 people in 67 countries. While Merck in Darmstadt is the legal successor of the original Merck and retains the rights to the name "Merck" in all countries except the U. S. and Canada, it is sometimes known as "Merck Darmstadt" in North America. The company was also referred to as "E. Merck". In 1973, Merck Ltd. acquired BDH Chemicals from the Glaxo Group. In the early 1980s Merck Group built a visitor center at its Darmstadt headquarters that featured a pyramid, the design of, controversial.
Merck was named E. Merck oHG until 1995. In 1995 it was listed on the Frankfurt Stock Exchange and became a KGaA named Merck KGaA. On March 13, 2006, Merck announced a takeover bid for Schering AG, the world's largest producer of oral contraceptives. On March 23, 2006, Bayer AG made a supported offer for Schering and Merck decided to drop out of the bidding for the company. Schering is not to be confused with Schering-Plough, once part of Schering AG but was acquired by Merck & Co. in 2009. In September 2006 the company announced a takeover bid of $13.2 billion for Serono SA, Switzerland's largest biotech firm. The deal included a buy-out of the Bertarelli family's 64.5% stake in Serono to be followed by a public tender offer for the remaining shares starting in November 2006. The combined company has an R&D budget of $1.1 billion and sales of $4.6 billion. Its $2 billion in sales of biologics would make it 7th among pharmaceutical/biotech companies; the new entity, Merck Serono, began operations in 2007.
In 2010 Merck took over Billerica based Millipore Corporation for EUR 5.3 billion. It is now Merck's life science business unit. With the acquisition of Millipore, Merck is consolidating its US holdings and shutting down the Gibbstown facility and warehouse. Gibbstown operations will be transferred to Millipore headquarters. Merck Korea received the "Leading Investor Award" at the 5th Korea-EU Industrial Cooperation Day in 2011. In December 2013, the company bought AZ Electronic Materials SA for about $2.6 billion in cash to increase its offering of specialty chemicals to the electronics industry. In September 2014 Merck halted the clinical development of two drug candidates in development with Oxygen Biotherapeutics. One drug candidate suffered a lack of success in patient recruitment, with its MUC1 antigen-specific cancer immunotherapy drug, missing its Phase I/II endpoint of increasing overall survival in patients with Stage III non-small cell lung cancer. In September it was announced that the company would